News for Biogen Inc. (IDP.DE)

**media[652503,652504]**

Biogen Inc. (NASDAQ:BIIB) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:40 AM ETCompany ParticipantsRobin C.

A Chinese company that developed the country’s first indigenous therapy for Alzheimer’s disease has suspended production and sales of the drug, casting doubts on the treatment’s future.

Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and

Long-established in the Drug Manufacturers industry, Biogen Inc (BIIB) has enjoyed a stellar reputation. It has recently witnessed a daily gain of 1.53%, juxtap

Sanofi has agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the company aims to expand the company's reach in rare immunological diseases. Blueprint Medicines shares were trading more than 26% higher ahead of US market open.

Long-established in the Drug Manufacturers industry, Biogen Inc (BIIB) has enjoyed a stellar reputation. However, it has recently witnessed a daily loss of 0.94

Biogen Inc. (NASDAQ:BIIB)’s recent partnership with City Therapeutics, Inc. to develop RNAi therapies for central nervous system diseases has fueled a 6% rise in its share price over the past month, reflecting renewed investor optimism. This move comes amid a broader rally in the tech sector driven by favorable policy shifts and positive market sentiment, […]

Biogen Inc. (NASDAQ:BIIB)’s recent partnership with City Therapeutics, Inc.

Summary Biogen Inc (BIIB) has announced a strategic collaboration with City Therapeutics, a leader in RNA interference (RNAi)-based medicine, to develop novel R

Mizuho has adjusted its price target for Biogen (BIIB), bringing it down from $207 to $169 while maintaining an Outperform rating. This revision follows an upda

On May 5, 2025, JP Morgan's analyst Chris Schott made a noteworthy update on Biogen (BIIB), maintaining a 'Neutral' rating while lowering the price target. The

JPMorgan has revised its price target for Biogen (BIIB), reducing it from $185 to $175 while maintaining a Neutral rating on the stock. This adjustment comes af

Biogen Inc. sees significant revenue growth from new products, contributing 45% of total revenue. Analysts predict substantial upside for Biogen stock w

Biogen Inc. (NASDAQ:BIIB) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ETCompany ParticipantsTim Power - Head, Investor RelationsChris Viehbacher -...

Biogen's revenue sees a 6.1% boost, driven by strategic product positioning. Analysts predict substantial potential upside with a high price target of $

Key Takeaways: Biogen Inc. (BIIB) posts strong quarterly results with non-GAAP EPS of $3.02. Analyst consensus targets an average price increase of nearl

The following slide deck was published by Biogen Inc.

Biogen (BIIB) has revised its financial guidance for the full year 2025. This update incorporates a $165 million upfront payment related to a transaction with S